Search results
Showing 61 to 75 of 84 results for colitis
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued
cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued
cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS114Show all sections
recommended for treating atopic dermatitis and tofacitinib for ulcerative colitis. Prescribing of Janus kinase (JAK) inhibitors has...
Source guidance details Comes from guidance Ulcerative colitis: management Number NG130 Date issued May 2019
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
In development [GID-TA11244] Expected publication date: TBC
This guidance has been updated and replaced by NICE guideline NG130.
Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)
This evidence summary has been updated and replaced by NICE guideline NG130.
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Moderately to severely active ulcerative colitis: adalimumab (ESNM6)
This evidence summary has been replaced by NICE technology appraisal guidance 329.
Infliximab for subacute manifestations of ulcerative colitis (TA140)
This guidance has been updated and replaced by NICE technology appraisal guidance 329.